RT Journal Article
SR Electronic
T1 REACT-1 round 12 report: resurgence of SARS-CoV-2 infections in England associated with increased frequency of the Delta variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.17.21259103
DO 10.1101/2021.06.17.21259103
A1 Riley, Steven
A1 Wang, Haowei
A1 Eales, Oliver
A1 Haw, David
A1 Walters, Caroline E.
A1 Ainslie, Kylie E. C.
A1 Atchison, Christina
A1 Fronterre, Claudio
A1 Diggle, Peter J.
A1 Page, Andrew J.
A1 Prosolek, Sophie J.
A1 Trotter, Alexander J.
A1 Le Viet, Thanh
A1 Alikhan, Nabil-Fareed
A1 Jackson, Leigh M
A1 Ludden, Catherine
A1 The COVID-19 Genomics UK (COG-UK) Consortium
A1 Ashby, Deborah
A1 Donnelly, Christl A.
A1 Cooke, Graham
A1 Barclay, Wendy
A1 Ward, Helen
A1 Darzi, Ara
A1 Elliott, Paul
YR 2021
UL http://medrxiv.org/content/early/2021/06/21/2021.06.17.21259103.abstract
AB Background England entered a third national lockdown from 6 January 2021 due to the COVID-19 pandemic. Despite a successful vaccine rollout during the first half of 2021, cases and hospitalisations have started to increase since the end of May as the SARS-CoV-2 Delta (B.1.617.2) variant increases in frequency. The final step of relaxation of COVID-19 restrictions in England has been delayed from 21 June to 19 July 2021.Methods The REal-time Assessment of Community Transmision-1 (REACT-1) study measures the prevalence of swab-positivity among random samples of the population of England. Round 12 of REACT-1 obtained self-administered swab collections from participants from 20 May 2021 to 7 June 2021; results are compared with those for round 11, in which swabs were collected from 15 April to 3 May 2021.Results Between rounds 11 and 12, national prevalence increased from 0.10% (0.08%, 0.13%) to 0.15% (0.12%, 0.18%). During round 12, we detected exponential growth with a doubling time of 11 (7.1, 23) days and an R number of 1.44 (1.20, 1.73). The highest prevalence was found in the North West at 0.26% (0.16%, 0.41%) compared to 0.05% (0.02%, 0.12%) in the South West. In the North West, the locations of positive samples suggested a cluster in Greater Manchester and the east Lancashire area. Prevalence in those aged 5-49 was 2.5 times higher at 0.20% (0.16%, 0.26%) compared with those aged 50 years and above at 0.08% (0.06%, 0.11%). At the beginning of February 2021, the link between infection rates and hospitalisations and deaths started to weaken, although in late April 2021, infection rates and hospital admissions started to reconverge. When split by age, the weakened link between infection rates and hospitalisations at ages 65 years and above was maintained, while the trends converged below the age of 65 years. The majority of the infections in the younger group occurred in the unvaccinated population or those without a stated vaccine history. We observed the rapid replacement of the Alpha (B.1.1.7) variant of SARS-CoV-2 with the Delta variant during the period covered by rounds 11 and 12 of the study.Discussion The extent to which exponential growth continues, or slows down as a consequence of the continued rapid roll-out of the vaccination programme, including to young adults, requires close monitoring. Data on community prevalence are vital to track the course of the epidemic and inform ongoing decisions about the timing of further lifting of restrictions in England.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Department of Health and Social Care in England.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We obtained research ethics approval from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated or analysed, or both, during this study are not publicly available because of governance restrictions.